Navigation Links
Isis Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:2/28/2012

CARLSBAD, Calif., Feb. 28, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Cowen and Company's 32nd Annual Health Care Conference on Tuesday, March 06, 2012 at 10:40 a.m. ET at the Boston Marriot Copley Place.  

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ALBANY, New York , September 30, 2014 /PRNewswire/ ... Market - Global Industry Analysis, Market Size, Share, Growth ... Research is expected to be worth USD 20.8 billion ... 29.5 billion in 2017, growing at a CAGR of ... are fundamental elements needed for various health purposes, especially ...
(Date:9/30/2014)...   Decision Resources Group finds that through ... kidney disease non-dialysis (CKD-ND) patients are not highly ... addition, one-year persistency is similar between Amgen,s Aranesp ... findings from the report entitled Treatment ... Agents in Late Stage Chronic Kidney Disease and ...
(Date:9/30/2014)... SAN DIEGO , 30. September ... Logo - http://photos.prnewswire.com/prnh/20130430/LA01948LOGO ... ein Medizintechnikunternehmen, das ein minimal-invasives 3D-Herzkammer-Bildgebungs- ... der Ursachen entwickelt, die zu komplexen ... aufrechterhalten, hat den Abschluss einer zusätzlichen ...
Breaking Medicine Technology:Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3
... InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company ... has completed enrollment of a 360 patient Phase 2b ... PPAR gamma (SPPARM) for the treatment of Type 2 ... dose active comparator (45mg Actos(R)) and placebo controlled study ...
... the nation,s economic slowdown, America,s pharmaceutical research and ... year in the research and development of new ... roughly $2 billion from 2007, according to analyses ... (PhRMA) and Burrill & Company. PhRMA-member companies ...
Cached Medicine Technology:InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 4
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, ... to put the brakes on motherhood. And for many young ... choice, new research suggests. Women in their early 20s ... during tough economic times. But, according to the new study, ... their 40s and beyond. The findings suggest that higher ...
(Date:9/30/2014)... the leading cause of cancer death in women, according ... medical professionals encourage women to get mammograms, even though ... of suspicious mammograms actually leads to a cancer diagnosis. ... women and their familiesnot to mention the time, discomfort ... , Recently, a different type of test, ultrasound ...
(Date:9/30/2014)... Dynamic health trends, changing consumer ... the Bread Production industry over the past five ... their consumption of a variety of industry goods ... the market for white loaf bread and other ... introducing more nutritious products to attract health-conscious consumers, ...
(Date:9/30/2014)... of Maryland-led research team has been awarded a ... of Health (NIH) to develop new imaging technologies ... understanding of how large networks of neurons in ... knowledge will help researchers identify the precise interactions ... like decision-making and speaking, and alterations in these ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
Breaking Medicine News(10 mins):Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:'Virtual breast' could improve cancer detection 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2
... Though nursing is thought to reduce risk, more advanced tumors ... Women who breast-feed for six months or more face a ... cancer, but it,s not clear whether there,s a cause-and-effect relationship, ... these women are more likely to die of cancer than ...
... ... Experience in Style , ... March 26, 2010 -- Last week EarPeace provided hearing protection to thousands of music ... bands over the course of four days. The average decibel level at a concert is ...
... ... local and national organizations to help individuals in need. , ... Munster, IN (PRWEB) March 26, 2010 -- ... its efforts in giving back to the community and helping individuals in need of ...
... alcohol use tied to better lifestyle habits, study finds ... take worse care of themselves than other people, but ... who don,t imbibe, researchers have found. , "The main ... other behaviors -- such as relieving stress with alcohol ...
... beta-blockers can help reduce the spread of cancer in ... seventh European Breast Cancer Conference (EBCC7) in Barcelona today ... senior healthcare research scientist at Queen,s Medical Centre, Nottingham ... found that the group of patients treated with beta-blockers ...
... Spain: Two studies to be presented at the seventh ... and tomorrow (Saturday), shed light on the treatment options ... which predispose them to breast cancer. In the first, ... of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands, ...
Cached Medicine News:Health News:Long-Term Breast-Feeding Tied to More Aggressive Cancers 2Health News:EarPeace Protects Hearing for Thousands at South by Southwest 2Health News:Stirling Dental Laboratory, Experts in Emergency Denture Repair Service, Gives Back to Community 2Health News:Stirling Dental Laboratory, Experts in Emergency Denture Repair Service, Gives Back to Community 3Health News:Heavy Daily Drinking Linked to Worse Health 2Health News:Beta-blockers help reduce metastasis and improve survival in breast cancer patients 2Health News:New studies on surgical options in inherited breast cancer show drastic treatment is not always best 2Health News:New studies on surgical options in inherited breast cancer show drastic treatment is not always best 3Health News:New studies on surgical options in inherited breast cancer show drastic treatment is not always best 4
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... The ITREL 3 is a battery powered ... the U.S., ,Enterra™ Therapy is indicated ... vomiting associated with gastroparesis when conventional drug ... symptons for diabetic or idiopathic patients., ...
... rapid qualitative test for detection of cardiac ... samples. It can be used as an ... and can be useful to assess if ... angina (e.g. gastric pain, strained chest muscles, ...
Medicine Products: